UCB SA (OTCMKTS:UCBJF) Given Consensus Rating of “Buy” by Brokerages

UCB SA (OTCMKTS:UCBJF) has received a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating.

A number of research analysts have issued reports on UCBJF shares. Wolfe Research began coverage on shares of UCB in a research report on Monday, February 23rd. They set an “outperform” rating on the stock. The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a research report on Monday, February 16th. Barclays reiterated an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of UCB in a research note on Monday, December 8th. Finally, Stephens reaffirmed an “overweight” rating on shares of UCB in a report on Thursday, January 15th.

UCB Price Performance

OTCMKTS:UCBJF opened at $276.21 on Friday. UCB has a 52 week low of $150.70 and a 52 week high of $345.39. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The firm’s 50-day simple moving average is $311.33 and its 200 day simple moving average is $288.32.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.